uric acid has been researched along with Left Ventricular Hypertrophy in 63 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies were identified by using MeSH terms and crossing the following search items: 'uric acid', 'hyperuricemia', 'left ventricular mass', 'left ventricular hypertrophy', 'echocardiography', 'female', 'male'." | 9.94 | Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies. ( Carugo, S; Cuspidi, C; Faggiano, A; Gherbesi, E; Grassi, G; Sala, C; Tadic, M, 2024) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 9.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 9.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 9.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| "To evaluate the condition of subclinical cardiac damage in children with primary hypertension and the association between serum uric acid and subclinical cardiac damage." | 8.02 | [Association between serum uric acid and subclinical cardiac damage in children with primary hypertension]. ( Cao, L; Ding, YY; Hou, M; Lyu, HT; Shen, J; Sun, L; Xu, QQ; Yang, DP; Zhou, WP, 2021) |
| "The level of serum uric acid (SUA) has been reported to be associated with left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD)." | 8.02 | Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. ( Kim, HJ; Kim, IY; Kim, MJ; Kim, SR; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Song, SH; Ye, BM, 2021) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 7.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "results indicate serum uric acid is positively correlated with hypertension and a reliable indicator of LVH in study population." | 7.96 | Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti. ( Adebayo, RA; Adewuya, OA; Ajayi, EA; Ojo, OE; Olaoye, OB, 2020) |
| " However, the dose-response effects of serum uric acid (SUA) on the prevalence of MetS and electrocardiographic left ventricular hypertrophy (LVH) are unclear." | 7.91 | The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. ( Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019) |
| "The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled." | 7.85 | Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Mancia, G; Sala, C; Tadic, M, 2017) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 7.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "Hyperhomocysteinemia (HHcy) is recognized as a risk factor for cardiovascular disease." | 7.83 | High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2016) |
| "Uric acid (UA) is associated with high blood pressure in adolescents and with left ventricular hypertrophy (LVH) and cardiovascular disease (CVD) in adults." | 7.81 | Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. ( Appel, LJ; Brady, TM; Fadrowski, JJ; Holmes, KW; Loeffler, LF; Miller, ER; Reschke, LD, 2015) |
| "Several studies have documented an association between serum uric acid (SUA) concentration and cardiac hypertrophy in hypertensive patients; however, the association remains unclear in chronic kidney disease (CKD) patients." | 7.80 | Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. ( Fukui, A; Ikeda, H; Kitazono, T; Nakayama, M; Oniki, H; Tsuchihashi, T; Tsuruya, K; Ura, Y; Yoshitomi, R, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 7.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| "Elevated uric acid (UA) level is reported to be related to the development of left ventricular hypertrophy (LVH) which is associated with high incidence of ventricular tachycardia (VT) and sudden cardiac death." | 7.78 | Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy. ( Kamioka, M; Kamiyama, Y; Saitoh, S; Suzuki, H; Takeishi, Y; Yamada, S, 2012) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 7.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| "The potential effect of uric acid on LV hypertrophy is more pronounced in female than in males with essential hypertension." | 7.73 | Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Ohtsubo, T; Oniki, H, 2006) |
| "To analyse relationships between left ventricular myocardium mass (LVMM) and imbalance of uric acid metabolism in patients with arterial hypertension (AH)." | 7.71 | [Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension]. ( Anikina, SA; Balkarov, IM; Donskov, AS; Feofanova, ID; Golub', GV; Prilepo, NA; Saltykova, NG; Sviderskaia, NS, 2001) |
| " Studies were identified by using MeSH terms and crossing the following search items: 'uric acid', 'hyperuricemia', 'left ventricular mass', 'left ventricular hypertrophy', 'echocardiography', 'female', 'male'." | 5.94 | Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies. ( Carugo, S; Cuspidi, C; Faggiano, A; Gherbesi, E; Grassi, G; Sala, C; Tadic, M, 2024) |
| "Uric acid (UA) was thought to induce cardiomyocyte growth and interstitial fibrosis of the heart, partly via activation of the renin-angiotensin system." | 5.35 | Uric acid and left ventricular hypertrophy in Japanese men. ( Hotta, Y; Kondo, T; Matsushita, K; Mitsuhashi, H; Muramatsu, T; Murohara, T; Otsuka, R; Takefuji, S; Tamakoshi, K; Toyoshima, H; Yatsuya, H; Zhang, H, 2009) |
| "Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]." | 5.33 | The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. ( Antoniadis, D; Chatzis, D; Dimitriadis, K; Kallikazaros, I; Lalos, S; Stefanadis, C; Toutouzas, P; Tsioufis, C; Vezali, E; Zervoudaki, A, 2005) |
| "It is unclear whether serum uric acid (SUA) is associated with development of new-onset diabetes (NOD) in patients with hypertension and left ventricular hypertrophy (LVH)." | 5.14 | Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study. ( Dahlöf, B; Devereux, RB; Høieggen, A; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Lindholm, L; Okin, PM; Olsen, MH; Wachtell, K; Wiik, BP, 2010) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 5.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "It is still undefined whether serum uric acid (SUA) is an independent risk factor for target organ damage (TOD) and cardiovascular events in human hypertension." | 5.12 | Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia. ( Cuspidi, C; Esposito, A; Mancia, G; Meani, S; Sala, C; Valerio, C; Zanchetti, A, 2007) |
| " We also tested whether the addition of an insulin resistance index (HOMA-index >90th percentile by sex and age) and the presence of hyperuricemia (serum uric acid >90th percentile by sex and age) to the definition of MUO better identified obese children with early cardiac damage." | 4.12 | Association of obesity phenotypes with left ventricular mass index and left ventricular hypertrophy in children and adolescents. ( Antolini, L; Genovesi, S; Giussani, M; Lieti, G; Montemerlo, M; Orlando, A; Parati, G; Patti, I; Tassistro, E, 2022) |
| "To evaluate the condition of subclinical cardiac damage in children with primary hypertension and the association between serum uric acid and subclinical cardiac damage." | 4.02 | [Association between serum uric acid and subclinical cardiac damage in children with primary hypertension]. ( Cao, L; Ding, YY; Hou, M; Lyu, HT; Shen, J; Sun, L; Xu, QQ; Yang, DP; Zhou, WP, 2021) |
| " Homeostasis model assessment index, serum uric acid level, and a ratio of triglycerides to high-density lipoprotein cholesterol were used as markers of the insulin resistance." | 4.02 | Insulin resistance surrogates and left ventricular hypertrophy in normotensive obese children. ( Bjelakovic, B; Bjelakovic, L; Bratic, M; Ciric, M; Lukic, S; Pantelic, S; Saranac, L; Stankovic, S; Vukovic, V, 2021) |
| "The level of serum uric acid (SUA) has been reported to be associated with left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD)." | 4.02 | Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease. ( Kim, HJ; Kim, IY; Kim, MJ; Kim, SR; Lee, DW; Lee, SB; Rhee, H; Seong, EY; Song, SH; Ye, BM, 2021) |
| "Results: Left ventricular mass index was significantly higher (р = 0,0498) in patients from the І group (109,7 ± 3,21) g/m2 comparable with the ІІ (97,6 ± 5,35) g/m2 and increased in proportion to the biggest level of uric acid (r = 0,31; p = 0,04) in patients with arterial hypertension and hyperuricemia." | 3.96 | Arterial hypertension associated with hyperuricemia: features of heart damage. ( Chernatska, OM; Fadieieva, HA; Liashenko, AV; Prystupa, LN; Smiianova, YO, 2020) |
| " This study was designed to evaluate the influences of long-term xanthine oxidase inhibitor (febuxostat) prescription on left ventricular hypertrophy (LVH), left ventricular (LV) diastolic function, and new-onset heart failure with preserved ejection fraction (HFpEF) in these patients." | 3.96 | Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia. ( Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF, 2020) |
| "results indicate serum uric acid is positively correlated with hypertension and a reliable indicator of LVH in study population." | 3.96 | Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti. ( Adebayo, RA; Adewuya, OA; Ajayi, EA; Ojo, OE; Olaoye, OB, 2020) |
| " However, the dose-response effects of serum uric acid (SUA) on the prevalence of MetS and electrocardiographic left ventricular hypertrophy (LVH) are unclear." | 3.91 | The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. ( Chang, WC; Chen, KH; Hwang, JJ; Liu, CW; Tseng, CK; Wu, YW, 2019) |
| "The association between serum uric acid (SUA) and left ventricular hypertrophy (LVH) is controversial and the ability of SUA in predicting incident LVH remains unsettled." | 3.85 | Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Mancia, G; Sala, C; Tadic, M, 2017) |
| "Although the relation between serum uric acid (SUA) and left ventricular hypertrophy (LVH) has been studied for decades, however, their association remains debatable." | 3.85 | Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease. ( Bao, H; Chen, Y; Cheng, D; Fan, Y; Jian, G; Li, J; Sheng, X; Wang, N; Zeng, C, 2017) |
| "Hyperhomocysteinemia (HHcy) is recognized as a risk factor for cardiovascular disease." | 3.83 | High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease. ( Li, Y; Lou, T; Ma, X; Peng, H; Wang, C; Ye, Z; Zhang, J; Zhang, Q, 2016) |
| " Hyperuricemia was defined according to sex-specific serum uric acid levels (SUA): SUA≥7." | 3.81 | Combination of hyperuricemia and metabolic syndrome is an independent and powerful predictor for left ventricular hypertrophy in rural Chinese. ( Guo, X; Sun, Y; Yang, H; Yu, S, 2015) |
| "Serum uric acid (SUA) is associated with the severity and prognosis of systolic heart failure." | 3.81 | Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction. ( Fujita, S; Hoshiga, M; Ishizaka, N; Ito, T; Kizawa, S; Morita, H; Nogi, S; Okamoto, Y; Sakane, K; Sohmiya, K, 2015) |
| "Uric acid (UA) is associated with high blood pressure in adolescents and with left ventricular hypertrophy (LVH) and cardiovascular disease (CVD) in adults." | 3.81 | Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth. ( Appel, LJ; Brady, TM; Fadrowski, JJ; Holmes, KW; Loeffler, LF; Miller, ER; Reschke, LD, 2015) |
| "The association of serum uric acid (UA) with left ventricular hypertrophy (LVH) remains controversial." | 3.80 | Serum uric acid is associated with the left ventricular mass index in males of a general population. ( Adachi, H; Enomoto, M; Fukami, A; Hirai, Y; Imaizumi, T; Kumagai, E; Nakamura, S; Nohara, Y; Obuchi, A; Ohbu, K; Yoshimura, A, 2014) |
| "Several studies have documented an association between serum uric acid (SUA) concentration and cardiac hypertrophy in hypertensive patients; however, the association remains unclear in chronic kidney disease (CKD) patients." | 3.80 | Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease. ( Fukui, A; Ikeda, H; Kitazono, T; Nakayama, M; Oniki, H; Tsuchihashi, T; Tsuruya, K; Ura, Y; Yoshitomi, R, 2014) |
| " The relationship between uric acid levels and left ventricular mass in hypertension, however, is unclear." | 3.80 | Uricaemia and left ventricular mass in hypertensive patients. ( Brosolo, G; Capobianco, F; Catena, C; Colussi, G; Sechi, LA, 2014) |
| "To assess the relationship between serum uric acid and target organ damage (left ventricular hypertrophy and microalbuminuria) in untreated patients with essential hypertension." | 3.80 | Serum uric acid and target organ damage in essential hypertension. ( Odia, OJ; Ofori, SN, 2014) |
| "There was direct relationship between level of CV risk and presence of additional risk factors (hyperglycemia, hyperuricemia, hyperfibrinogenemia, left ventricular hypertrophy)." | 3.80 | [Detection of early markers of atherosclerosis in men with various levels of risk of cardiovascular complications]. ( Badeĭnikova, KK; Didigova, RT; Mamedov, MN; Mazaev, AP; Toguzova, ZA, 2014) |
| "Hyperuricemia and left ventricular (LV) hypertrophy are prevalent in chronic kidney disease (CKD), but the association of uric acid (UA) and left ventricular mass index (LVMI) with renal outcomes in patients with CKD is unclear." | 3.79 | Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease. ( Chang, JM; Chen, HC; Chen, SC; Su, HM; Yeh, SM, 2013) |
| "Elevated uric acid (UA) level is reported to be related to the development of left ventricular hypertrophy (LVH) which is associated with high incidence of ventricular tachycardia (VT) and sudden cardiac death." | 3.78 | Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy. ( Kamioka, M; Kamiyama, Y; Saitoh, S; Suzuki, H; Takeishi, Y; Yamada, S, 2012) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 3.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| " Serum uric acid and higher birth weight are predictors of LVM." | 3.73 | Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension. ( Antoniewicz, J; Daszkowska, J; Grenda, R; Litwin, M; Niemirska, A; Sladowska, J; Wawer, ZT; Wierzbicka, A, 2006) |
| "The potential effect of uric acid on LV hypertrophy is more pronounced in female than in males with essential hypertension." | 3.73 | Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. ( Fujii, K; Iida, M; Matsumura, K; Ohtsubo, T; Oniki, H, 2006) |
| "To analyse relationships between left ventricular myocardium mass (LVMM) and imbalance of uric acid metabolism in patients with arterial hypertension (AH)." | 3.71 | [Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension]. ( Anikina, SA; Balkarov, IM; Donskov, AS; Feofanova, ID; Golub', GV; Prilepo, NA; Saltykova, NG; Sviderskaia, NS, 2001) |
| "Chronic kidney disease and left ventricular hypertrophy are potent modifiers of the prognostic value of the circadian BP changes." | 1.72 | Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes. ( Angeli, F; Reboldi, G; Verdecchia, P, 2022) |
| "The decrease in the prevalence of left ventricular hypertrophy after renal transplantation is blunted by high sodium intake." | 1.40 | Left ventricular mass changes after renal transplantation: influence of dietary sodium and change in serum uric acid. ( Bonnet, B; du Cailar, G; Fesler, P; Mimran, A; Mourad, G; Oudot, C; Pernin, V; Ribstein, J, 2014) |
| "Uric acid (UA) was thought to induce cardiomyocyte growth and interstitial fibrosis of the heart, partly via activation of the renin-angiotensin system." | 1.35 | Uric acid and left ventricular hypertrophy in Japanese men. ( Hotta, Y; Kondo, T; Matsushita, K; Mitsuhashi, H; Muramatsu, T; Murohara, T; Otsuka, R; Takefuji, S; Tamakoshi, K; Toyoshima, H; Yatsuya, H; Zhang, H, 2009) |
| "Moreover, according to the presence of left ventricular hypertrophy (LVH) the participants were subdivided into two additional groups: [LVH (+), n=305 and LVH (-), n=537]." | 1.33 | The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage. ( Antoniadis, D; Chatzis, D; Dimitriadis, K; Kallikazaros, I; Lalos, S; Stefanadis, C; Toutouzas, P; Tsioufis, C; Vezali, E; Zervoudaki, A, 2005) |
| "Metabolic syndrome is associated with subclinical organ damage in nondiabetic, essential hypertensive patients." | 1.33 | Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. ( Deferrari, G; Falqui, V; Leoncini, G; Parodi, A; Parodi, D; Pontremoli, R; Ratto, E; Tomolillo, C; Vaccaro, V; Viazzi, F, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 13 (20.63) | 29.6817 |
| 2010's | 32 (50.79) | 24.3611 |
| 2020's | 16 (25.40) | 2.80 |
| Authors | Studies |
|---|---|
| Verdecchia, P | 1 |
| Angeli, F | 1 |
| Reboldi, G | 2 |
| Genovesi, S | 1 |
| Tassistro, E | 1 |
| Giussani, M | 1 |
| Lieti, G | 1 |
| Patti, I | 1 |
| Orlando, A | 1 |
| Montemerlo, M | 1 |
| Antolini, L | 1 |
| Parati, G | 2 |
| Shui, W | 1 |
| Wang, J | 1 |
| Cui, T | 1 |
| Kang, C | 1 |
| Zhang, Z | 1 |
| Muiesan, ML | 1 |
| Agabiti Rosei, C | 1 |
| Paini, A | 1 |
| Casiglia, E | 1 |
| Cirillo, M | 1 |
| Grassi, G | 3 |
| Iaccarino, G | 1 |
| Mallamaci, F | 1 |
| Maloberti, A | 1 |
| Mazza, A | 1 |
| Mengozzi, A | 1 |
| Palatini, P | 1 |
| Rivasi, G | 1 |
| Russo, E | 1 |
| Salvetti, M | 1 |
| Tikhonoff, V | 1 |
| Tocci, G | 2 |
| Borghi, C | 3 |
| Kjeldsen, SE | 3 |
| Mariampillai, JE | 1 |
| Høieggen, A | 2 |
| Gherbesi, E | 1 |
| Faggiano, A | 1 |
| Sala, C | 3 |
| Carugo, S | 1 |
| Tadic, M | 2 |
| Cuspidi, C | 3 |
| Kishi, T | 1 |
| Bjelakovic, B | 2 |
| Stefanutti, C | 1 |
| Bonic, D | 1 |
| Vukovic, V | 2 |
| Kavaric, N | 1 |
| Saranac, L | 2 |
| Kocic, G | 1 |
| Klisic, A | 1 |
| Jevtović Stojmenov, T | 1 |
| Lukic, S | 2 |
| Jovic, M | 1 |
| Bjelakovic, M | 1 |
| Obrycki, Ł | 1 |
| Feber, J | 1 |
| Derezinski, T | 1 |
| Lewandowska, W | 1 |
| Kułaga, Z | 1 |
| Litwin, M | 2 |
| Kanbay, M | 2 |
| Girerd, N | 1 |
| Machu, JL | 1 |
| Bozec, E | 1 |
| Duarte, K | 1 |
| Boivin, JM | 1 |
| Wagner, S | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 1 |
| Rossignol, P | 1 |
| Chernatska, OM | 1 |
| Prystupa, LN | 1 |
| Fadieieva, HA | 1 |
| Liashenko, AV | 1 |
| Smiianova, YO | 1 |
| Pan, JA | 1 |
| Lin, H | 1 |
| Wang, CQ | 1 |
| Zhang, JF | 1 |
| Gu, J | 1 |
| Cai, A | 1 |
| Liu, L | 1 |
| Siddiqui, M | 1 |
| Zhou, D | 1 |
| Chen, J | 1 |
| Calhoun, DA | 1 |
| Tang, S | 1 |
| Zhou, Y | 1 |
| Feng, Y | 1 |
| Adewuya, OA | 1 |
| Ajayi, EA | 1 |
| Adebayo, RA | 1 |
| Ojo, OE | 1 |
| Olaoye, OB | 1 |
| Hou, M | 1 |
| Sun, L | 1 |
| Zhou, WP | 1 |
| Ding, YY | 1 |
| Xu, QQ | 1 |
| Cao, L | 1 |
| Shen, J | 1 |
| Yang, DP | 1 |
| Lyu, HT | 1 |
| Bjelakovic, L | 1 |
| Stankovic, S | 1 |
| Ciric, M | 1 |
| Bratic, M | 1 |
| Pantelic, S | 1 |
| Kim, IY | 1 |
| Ye, BM | 1 |
| Kim, MJ | 1 |
| Kim, SR | 1 |
| Lee, DW | 1 |
| Kim, HJ | 1 |
| Rhee, H | 1 |
| Song, SH | 1 |
| Seong, EY | 1 |
| Lee, SB | 1 |
| Yamauchi, Y | 1 |
| Fujita, SI | 1 |
| Shibata, K | 2 |
| Morita, H | 3 |
| Ito, T | 3 |
| Sohmiya, K | 3 |
| Hoshiga, M | 3 |
| Ishizaka, N | 3 |
| Zeng, C | 1 |
| Cheng, D | 1 |
| Sheng, X | 1 |
| Jian, G | 1 |
| Fan, Y | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Bao, H | 1 |
| Wang, N | 1 |
| Noma, K | 1 |
| Kihara, Y | 1 |
| Higashi, Y | 1 |
| Liu, CW | 1 |
| Chen, KH | 1 |
| Tseng, CK | 1 |
| Chang, WC | 1 |
| Wu, YW | 1 |
| Hwang, JJ | 1 |
| Szwejkowski, BR | 1 |
| Gandy, SJ | 1 |
| Rekhraj, S | 1 |
| Houston, JG | 1 |
| Lang, CC | 1 |
| Morris, AD | 1 |
| George, J | 1 |
| Struthers, AD | 1 |
| Yoshitomi, R | 1 |
| Fukui, A | 1 |
| Nakayama, M | 1 |
| Ura, Y | 1 |
| Ikeda, H | 1 |
| Oniki, H | 2 |
| Tsuchihashi, T | 1 |
| Tsuruya, K | 1 |
| Kitazono, T | 1 |
| Fujita, S | 2 |
| Okamoto, Y | 2 |
| Yoshimura, A | 1 |
| Adachi, H | 1 |
| Hirai, Y | 1 |
| Enomoto, M | 1 |
| Fukami, A | 1 |
| Kumagai, E | 1 |
| Ohbu, K | 1 |
| Nakamura, S | 1 |
| Obuchi, A | 1 |
| Nohara, Y | 1 |
| Imaizumi, T | 1 |
| Ofori, SN | 1 |
| Odia, OJ | 1 |
| Wang, CJ | 1 |
| Bao, XR | 1 |
| Du, GW | 1 |
| Wang, Y | 1 |
| Chen, K | 1 |
| Shen, ML | 1 |
| Wang, LZ | 1 |
| du Cailar, G | 1 |
| Oudot, C | 1 |
| Fesler, P | 1 |
| Mimran, A | 1 |
| Bonnet, B | 1 |
| Pernin, V | 1 |
| Ribstein, J | 1 |
| Mourad, G | 1 |
| Badeĭnikova, KK | 1 |
| Mazaev, AP | 1 |
| Toguzova, ZA | 1 |
| Mamedov, MN | 1 |
| Didigova, RT | 1 |
| Catena, C | 1 |
| Colussi, G | 1 |
| Capobianco, F | 1 |
| Brosolo, G | 1 |
| Sechi, LA | 1 |
| Jia, G | 1 |
| Habibi, J | 1 |
| Bostick, BP | 1 |
| Ma, L | 1 |
| DeMarco, VG | 1 |
| Aroor, AR | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, AT | 1 |
| Sowers, JR | 1 |
| Cicero, AF | 2 |
| Rosticci, M | 2 |
| Reggi, A | 1 |
| Derosa, G | 1 |
| Parini, A | 1 |
| Grandi, E | 1 |
| D'Addato, S | 2 |
| Mulè, G | 1 |
| Nardi, E | 1 |
| Guarino, L | 1 |
| Cacciatore, V | 1 |
| Geraci, G | 1 |
| Calcaterra, I | 1 |
| Oddo, B | 1 |
| Vaccaro, F | 1 |
| Cottone, S | 1 |
| Bacchelli, S | 1 |
| Urso, R | 1 |
| Reschke, LD | 1 |
| Miller, ER | 1 |
| Fadrowski, JJ | 1 |
| Loeffler, LF | 1 |
| Holmes, KW | 1 |
| Appel, LJ | 1 |
| Brady, TM | 1 |
| Yu, S | 2 |
| Guo, X | 2 |
| Yang, H | 2 |
| Sun, Y | 2 |
| Nogi, S | 1 |
| Kizawa, S | 1 |
| Sakane, K | 1 |
| Zheng, L | 1 |
| Liang, WY | 1 |
| Liu, WW | 1 |
| Liu, ML | 1 |
| Xiang, W | 1 |
| Feng, XR | 1 |
| Huang, B | 1 |
| Chen, XH | 1 |
| Sun, YS | 1 |
| Ye, Z | 1 |
| Zhang, Q | 1 |
| Li, Y | 1 |
| Wang, C | 1 |
| Zhang, J | 1 |
| Ma, X | 1 |
| Peng, H | 1 |
| Lou, T | 1 |
| Facchetti, R | 1 |
| Bombelli, M | 1 |
| Mancia, G | 2 |
| Kuwabara, M | 1 |
| Sato, Y | 1 |
| Johnson, RJ | 1 |
| Mitsuhashi, H | 1 |
| Yatsuya, H | 1 |
| Matsushita, K | 1 |
| Zhang, H | 1 |
| Otsuka, R | 1 |
| Muramatsu, T | 1 |
| Takefuji, S | 1 |
| Hotta, Y | 1 |
| Kondo, T | 1 |
| Murohara, T | 1 |
| Toyoshima, H | 1 |
| Tamakoshi, K | 1 |
| Saitoh, S | 2 |
| Wiik, BP | 1 |
| Larstorp, AC | 1 |
| Olsen, MH | 1 |
| Ibsen, H | 1 |
| Lindholm, L | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
| Okin, PM | 1 |
| Wachtell, K | 1 |
| Xaplanteris, P | 1 |
| Vlachopoulos, C | 1 |
| Vyssoulis, G | 1 |
| Terentes-Printzios, D | 1 |
| Alexopoulos, N | 1 |
| Lazaros, G | 1 |
| Stefanadis, C | 2 |
| Hu, YF | 1 |
| Chen, SA | 1 |
| Yeh, HI | 1 |
| Chen, CC | 1 |
| Hsu, YJ | 1 |
| Lee, TM | 1 |
| Yamada, S | 1 |
| Suzuki, H | 1 |
| Kamioka, M | 1 |
| Kamiyama, Y | 1 |
| Takeishi, Y | 1 |
| Chen, SC | 1 |
| Chang, JM | 1 |
| Yeh, SM | 1 |
| Su, HM | 1 |
| Chen, HC | 1 |
| Höieggen, A | 1 |
| Fossum, E | 1 |
| Reims, H | 1 |
| Tsioufis, C | 1 |
| Chatzis, D | 1 |
| Vezali, E | 1 |
| Dimitriadis, K | 1 |
| Antoniadis, D | 1 |
| Zervoudaki, A | 1 |
| Lalos, S | 1 |
| Kallikazaros, I | 1 |
| Toutouzas, P | 1 |
| Viazzi, F | 2 |
| Parodi, D | 2 |
| Leoncini, G | 2 |
| Parodi, A | 2 |
| Falqui, V | 2 |
| Ratto, E | 2 |
| Vettoretti, S | 1 |
| Bezante, GP | 1 |
| Del Sette, M | 1 |
| Deferrari, G | 2 |
| Pontremoli, R | 2 |
| Vaccaro, V | 1 |
| Tomolillo, C | 1 |
| Kurata, A | 1 |
| Shigematsu, Y | 1 |
| Higaki, J | 1 |
| Niemirska, A | 1 |
| Sladowska, J | 1 |
| Antoniewicz, J | 1 |
| Daszkowska, J | 1 |
| Wierzbicka, A | 1 |
| Wawer, ZT | 1 |
| Grenda, R | 1 |
| Matsumura, K | 1 |
| Ohtsubo, T | 1 |
| Fujii, K | 1 |
| Iida, M | 1 |
| Anan, F | 1 |
| Yonemochi, H | 1 |
| Masaki, T | 1 |
| Takahashi, N | 1 |
| Fukunaga, N | 1 |
| Teshima, Y | 1 |
| Iwao, T | 1 |
| Kaneda, K | 1 |
| Eshima, N | 1 |
| Saikawa, T | 1 |
| Yoshimatsu, H | 1 |
| Valerio, C | 1 |
| Meani, S | 1 |
| Esposito, A | 1 |
| Zanchetti, A | 1 |
| Ge, CJ | 1 |
| Lu, SZ | 1 |
| Chen, YD | 1 |
| Wu, XF | 1 |
| Hu, SJ | 1 |
| Ji, Y | 1 |
| Tomura, S | 1 |
| Kawada, K | 1 |
| Saito, K | 1 |
| Lin, YL | 1 |
| Endou, K | 1 |
| Hirano, C | 1 |
| Yanagi, H | 1 |
| Tsuchiya, S | 1 |
| Shiba, K | 1 |
| Martínez, MA | 1 |
| García-Puig, J | 1 |
| Martín, JC | 1 |
| Guallar-Castillón, P | 1 |
| Aguirre de Cárcer, A | 1 |
| Torre, A | 1 |
| Armada, E | 1 |
| Nevado, A | 1 |
| Madero, RS | 1 |
| Donskov, AS | 1 |
| Balkarov, IM | 1 |
| Golub', GV | 1 |
| Anikina, SA | 1 |
| Saltykova, NG | 1 |
| Sviderskaia, NS | 1 |
| Prilepo, NA | 1 |
| Feofanova, ID | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Dose-response Effect of Serum Uric Acid on the Prevalence and Electrocardiographic Left Ventricular Hypertrophy in the Apparently Healthy Individuals[NCT03473951] | 18,000 participants (Anticipated) | Observational | 2018-03-26 | Recruiting | |||
| A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)[NCT03353298] | Phase 2 | 71 participants (Actual) | Interventional | 2018-01-17 | Completed | ||
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for uric acid and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Uric acid and left ventricular hypertrophy: a gender-based meta-analysis of echocardiographic studies.
Topics: Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; | 2024 |
7 trials available for uric acid and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy.
Topics: Aged; Allopurinol; Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hea | 2013 |
Serum uric acid is associated with left ventricular hypertrophy independent of serum parathyroid hormone in male cardiac patients.
Topics: Aged; Biomarkers; Diuretics; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Parathyroid H | 2013 |
Serum uric acid is associated with new-onset diabetes in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Topics: Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hy | 2010 |
Serum uric acid and hemorheology in borderline hypertensives and in subjects with established hypertension and left ventricular hypertrophy.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Viscosity; Body Mass Index; Glucose Clamp Technique; H | 2003 |
Lack of association between serum uric acid and organ damage in a never-treated essential hypertensive population at low prevalence of hyperuricemia.
Topics: Adult; Albuminuria; Carotid Artery Diseases; Female; Humans; Hypertension; Hypertrophy, Left Ventric | 2007 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Sy | 2008 |
Frequency and determinants of white coat hypertension in mild to moderate hypertension: a primary care-based study. Monitorización Ambulatoria de la Presión Arterial (MAPA)-Area 5 Working Group.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure Determination; Blood Pressure Monitoring, Am | 1999 |
55 other studies available for uric acid and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Chronic Kidney Disease and Left Ventricular Hypertrophy. Potent Modifiers of the Prognostic Impact of Circadian Blood Pressure Changes.
Topics: Bayes Theorem; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Huma | 2022 |
Association of obesity phenotypes with left ventricular mass index and left ventricular hypertrophy in children and adolescents.
Topics: Child; Female; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Insulin Resistance; Male; Metab | 2022 |
Serum uric acid is related to left ventricular geometry and function in patients with obstructive sleep apnea.
Topics: Echocardiography; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Sleep Apnea, Obstructive; | 2023 |
Serum uric acid and left ventricular mass index independently predict cardiovascular mortality: The uric acid right for heart health (URRAH) project.
Topics: Echocardiography; Female; Heart; Humans; Hypertrophy, Left Ventricular; Male; Risk Factors; Uric Aci | 2023 |
Uric acid and left ventricular mass in prediction of cardiovascular risk-New insight from the URRAH study.
Topics: Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Hypertension; Hypertrophy, Left Ventric | 2023 |
Gender differences in the association of serum uric acid with left ventricular hypertrophy should be focused.
Topics: Humans; Hypertension; Hypertrophy, Left Ventricular; Risk Factors; Sex Factors; Uric Acid | 2024 |
Serum uric acid and left ventricular geometry pattern in obese children.
Topics: Adolescent; Case-Control Studies; Child; Cross-Sectional Studies; Female; Humans; Hypertrophy, Left | 2019 |
Hemodynamic Patterns and Target Organ Damage in Adolescents With Ambulatory Prehypertension.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Carotid Intima-Media Thickness; Female; Heart Ven | 2020 |
Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up.
Topics: Adult; Aged; Albuminuria; Blood Pressure; Cohort Studies; Creatinine; Female; France; Glomerular Fil | 2020 |
Arterial hypertension associated with hyperuricemia: features of heart damage.
Topics: Heart Injuries; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Uric Acid | 2020 |
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progr | 2020 |
Uric Acid Is Not Associated With Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes.
Topics: Albuminuria; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Correla | 2021 |
Serum uric acid and left ventricular hypertrophy in hypertensive patients in Ado-Ekiti.
Topics: Aged; Body Mass Index; Case-Control Studies; Cross-Sectional Studies; Echocardiography; Female; Huma | 2020 |
[Association between serum uric acid and subclinical cardiac damage in children with primary hypertension].
Topics: Blood Pressure; Child; Humans; Hypertension; Hypertrophy, Left Ventricular; Retrospective Studies; U | 2021 |
Insulin resistance surrogates and left ventricular hypertrophy in normotensive obese children.
Topics: Child; Cross-Sectional Studies; Humans; Hypertrophy, Left Ventricular; Insulin Resistance; Pediatric | 2021 |
Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease.
Topics: Biomarkers; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertrophy, Left Ventricular | 2021 |
Is Serum Uric Acid Independently Associated With Left Ventricular Mass Index, Ejection Fraction, and B-Type Natriuretic Peptide Among Female and Male Cardiac Patients?
Topics: Aged; Echocardiography; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Heart Ventricles; Hu | 2017 |
Increased Serum Uric Acid Level Is a Risk Factor for Left Ventricular Hypertrophy but Not Independent of eGFR in Patients with Type 2 Diabetic Kidney Disease.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; | 2017 |
Is Serum Uric Acid a Biomarker, but not a Mediator in Patients With Lifestyle and Cardiovascular Diseases?
Topics: Aged; Biomarkers; Cardiovascular Diseases; Female; Humans; Hypertrophy, Left Ventricular; Hyperurice | 2017 |
The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals.
Topics: Adult; Biomarkers; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Hyperuricemia | 2019 |
Sex differences in the association between serum uric acid levels and cardiac hypertrophy in patients with chronic kidney disease.
Topics: Adult; Aged; Aging; Cardiomegaly; Cross-Sectional Studies; Disease Progression; Echocardiography; Fe | 2014 |
Serum uric acid is associated with the left ventricular mass index in males of a general population.
Topics: Aged; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male | 2014 |
Serum uric acid and target organ damage in essential hypertension.
Topics: Adult; Aged; Albuminuria; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Female; Humans; | 2014 |
Effects of insulin resistance on left ventricular hypertrophy in patients with CKD stage 1-3.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Blood Urea Nitrogen; C-Re | 2014 |
Left ventricular mass changes after renal transplantation: influence of dietary sodium and change in serum uric acid.
Topics: Adult; Biomarkers; Blood Pressure; Diet, Sodium-Restricted; Female; France; Glomerular Filtration Ra | 2014 |
[Detection of early markers of atherosclerosis in men with various levels of risk of cardiovascular complications].
Topics: Adult; Ankle Brachial Index; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Carotid Arteries; | 2014 |
Uricaemia and left ventricular mass in hypertensive patients.
Topics: Blood Glucose; Cross-Sectional Studies; Echocardiography; Female; Humans; Hypertension; Hypertrophy, | 2014 |
Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet.
Topics: Allopurinol; Animals; Biomarkers; Diet, Western; Dietary Fats; Dietary Sucrose; Disease Models, Anim | 2015 |
Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Biomarkers; Electrocardiography; F | 2015 |
Plasma aldosterone and its relationship with left ventricular mass in hypertensive patients with early-stage chronic kidney disease.
Topics: Adult; Aged; Aldosterone; Blood Pressure; Creatinine; Female; Humans; Hypertension; Hypertrophy, Lef | 2015 |
Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort.
Topics: Aged; Cohort Studies; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Italy; Mal | 2015 |
Elevated uric acid and obesity-related cardiovascular disease risk factors among hypertensive youth.
Topics: Adolescent; Blood Pressure; Child; Child, Preschool; Cross-Sectional Studies; Echocardiography; Fema | 2015 |
Combination of hyperuricemia and metabolic syndrome is an independent and powerful predictor for left ventricular hypertrophy in rural Chinese.
Topics: Adult; Aged; Anthropometry; Asian People; Body Mass Index; China; Cross-Sectional Studies; Female; H | 2015 |
Serum uric acid is associated with cardiac diastolic dysfunction among women with preserved ejection fraction.
Topics: Aged; Aged, 80 and over; Biomarkers; Diastole; Female; Heart Failure; Humans; Hypertrophy, Left Vent | 2015 |
Hyperuricemia is independently associated with left ventricular hypertrophy in post-menopausal women but not in pre-menopausal women in rural Northeast China.
Topics: Adult; Age Factors; Aged; Body Mass Index; China; Diabetes Mellitus; Dyslipidemias; Female; Humans; | 2015 |
Serum uric acid level and left ventricular hypertrophy in elderly male patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Chi-Square Distribution; Huma | 2016 |
High Prevalence of Hyperhomocysteinemia and Its Association with Target Organ Damage in Chinese Patients with Chronic Kidney Disease.
Topics: Adult; Calcium Phosphates; Carotid Arteries; Carotid Intima-Media Thickness; Cross-Sectional Studies | 2016 |
Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population.
Topics: Adult; Aged; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Echocardiograph | 2017 |
Uric Acid and Left Ventricular Hypertrophy: A Potentially New Modifiable Target?
Topics: Humans; Hypertension; Hypertrophy, Left Ventricular; Sex Factors; Uric Acid | 2017 |
Uric acid and left ventricular hypertrophy in Japanese men.
Topics: Adult; Age Factors; Aged; Animals; Asian People; Body Mass Index; Cohort Studies; Creatinine; Diabet | 2009 |
Uric acid and left ventricular hypertrophy.
Topics: Adult; Age Factors; Aged; Animals; Asian People; Body Mass Index; Cohort Studies; Creatinine; Diabet | 2009 |
Uric acid levels, left ventricular mass and geometry in newly diagnosed, never treated hypertension.
Topics: Blood Flow Velocity; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; | 2011 |
Metabolic syndrome does not impose greater atrial fibrillation risk in elderly hypertensive patients.
Topics: Age Factors; Aged; Atrial Fibrillation; Creatinine; Diuretics; Female; Humans; Hypertension; Hypertr | 2010 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; D | 2011 |
Uric acid increases the incidence of ventricular arrhythmia in patients with left ventricular hypertrophy.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Biomarkers; Female; Humans; Hypertrophy, Left Ventric | 2012 |
Association of uric acid and left ventricular mass index with renal outcomes in chronic kidney disease.
Topics: Aged; Comorbidity; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration | 2013 |
The controversial role of serum uric acid in essential hypertension: relationships with indices of target organ damage.
Topics: Albuminuria; Biomarkers; Blood Pressure; Body Mass Index; Echocardiography; Female; Follow-Up Studie | 2005 |
Serum uric acid and target organ damage in primary hypertension.
Topics: Adult; Albuminuria; Biomarkers; Carotid Artery Diseases; Female; Humans; Hypertension; Hypertrophy, | 2005 |
Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients.
Topics: Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Carotid | 2005 |
Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients.
Topics: Aged; Cardiovascular Diseases; Case-Control Studies; Female; Humans; Hypertension; Hypertrophy, Left | 2005 |
Left ventricular hypertrophy and arterial wall thickening in children with essential hypertension.
Topics: Adolescent; Animals; Apolipoprotein A-I; Birth Weight; Blood Pressure; Carotid Arteries; Child; Chil | 2006 |
Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension.
Topics: Age Factors; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Case-Control Studies; Female; Hu | 2006 |
High-density lipoprotein cholesterol and insulin resistance are independent and additive markers of left ventricular hypertrophy in essential hypertension.
Topics: Aged; Biomarkers; Blood Pressure Determination; Cholesterol, HDL; Female; Humans; Hypertension; Hype | 2007 |
Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Albuminuria; Blood Glucose; Blood Proteins; Chi-Square | 1999 |
[Relationship between mass of the left ventricular myocardium and uric acid metabolic imbalance in patients with arterial hypertension].
Topics: Adult; Albuminuria; Body Mass Index; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Ki | 2001 |